Exploring the role of LPC16:0 in fibromyalgia
Official title: A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia
Run by Kaohsiung Medical University Chung-Ho Memorial Hospital · NCT04832100 · Data updated 2026-11-12
This study is trying to see how a specific compound called LPC16:0 affects people with fibromyalgia to help find better ways to diagnose and treat the condition.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 245 (estimated) |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Status | Recruiting |
| Started | June 1, 2021 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | June 26, 2025 |
| Trial ID | NCT04832100 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals with a clinical diagnosis of fibromyalgia.
✕Probably not a fit
Patients with systemic rheumatological disorders, chronic diseases under poor control, or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the significance of lysophosphatidylcholine (LPC16:0) in patients diagnosed with fibromyalgia, a condition characterized by chronic widespread pain and various comorbidities such as fatigue and anxiety. The study aims to explore the underlying mechanisms of fibromyalgia through advanced metabolomic techniques, which may help identify potential biomarkers for diagnosis and treatment. Participants will be assessed based on their clinical diagnosis and will receive treatments like pregabalin and imipramine as part of their management plan.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that improve the diagnosis and treatment of fibromyalgia.
How similar studies have gone: While there have been studies exploring various aspects of fibromyalgia, the specific focus on LPC16:0 and its implications is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Clinical diagnosis of fibromyalgia Exclusion Criteria: 1. Systemic rheumatological or immune disorders (e.g., systemic lupus erythematosus, inflammatory myositis), 2. Systemic use of corticosteroids, 3. Pregnancy, 4. Chronic diseases under poor control 5. Malignancies.
Where it's running
-
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Diabetes, Dementia, and Oxidative Stress: A look at Nox2-related markers
This study tests whether oxidative stress linked to Nox2 is related to dementia risk in adults with type 2 diabetes.
-
Barley and kefir to support gut health in active adults
This study tests whether a daily barley and kefir meal for four weeks can change gut microbiota in physically active adults and whether those changes relate to certain metabolites in blood and urine.
-
Opioid-Free vs Opioid-Based Anesthesia for Thyroid Surgery
This study tests whether a non-opioid anesthesia approach can match or improve outcomes for adults undergoing thyroidectomy.
-
Training to reduce oxidative stress in knee OA
A six-week program compares supervised knee-strengthening training with a daily 6,000-step walking plan to see if it improves pain, function, and blood markers of cellular stress in people with knee osteoarthritis.
-
Ashwagandha with resistance training to boost strength and stress markers
This 12-week study tests whether taking ASHWAGANDHA along with regular resistance training helps healthy, trained men see improvements in strength, stress levels, sleep, and cognitive function compared with a placebo.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.